{"protocolSection": {"identificationModule": {"nctId": "NCT01658657", "orgStudyIdInfo": {"id": "12-1133"}, "organization": {"fullName": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "briefTitle": "A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension", "officialTitle": "A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-10"}, "primaryCompletionDateStruct": {"date": "2014-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-07-31", "studyFirstSubmitQcDate": "2012-08-02", "studyFirstPostDateStruct": {"date": "2012-08-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-06-03", "resultsFirstSubmitQcDate": "2015-06-03", "resultsFirstPostDateStruct": {"date": "2015-06-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-08-17", "lastUpdatePostDateStruct": {"date": "2015-08-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Anthony J Viera, MD, MPH", "investigatorTitle": "Distinguished Associate Professor", "investigatorAffiliation": "University of North Carolina, Chapel Hill"}, "leadSponsor": {"name": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "collaborators": [{"name": "Cornell University", "class": "OTHER"}, {"name": "Wake Forest University Health Sciences", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment. Plasma renin is an enzyme in your blood that can be measured to determine your hypertension subtype. Once the subtype is known, doctors can prescribe specific medications to target your specific hypertension subtype. This study will investigate whether targeting the specific hypertension subtype helps to achieve blood pressure control sooner and with fewer medications compared to a standard fixed dose combination therapy."}, "conditionsModule": {"conditions": ["Hypertension", "Plasma Renin Activity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 17, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "PRA-guided therapy", "type": "EXPERIMENTAL", "description": "Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.", "interventionNames": ["Drug: Hydrochlorothiazide", "Drug: Lisinopril", "Drug: Amlodipine", "Drug: metoprolol"]}, {"label": "Fixed-dose combination treatment-guided therapy", "type": "ACTIVE_COMPARATOR", "description": "Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.", "interventionNames": ["Drug: Amlodipine", "Drug: metoprolol", "Drug: lisinopril/hydrochlorothiazide"]}], "interventions": [{"type": "DRUG", "name": "Hydrochlorothiazide", "armGroupLabels": ["PRA-guided therapy"]}, {"type": "DRUG", "name": "Lisinopril", "armGroupLabels": ["PRA-guided therapy"]}, {"type": "DRUG", "name": "Amlodipine", "armGroupLabels": ["Fixed-dose combination treatment-guided therapy", "PRA-guided therapy"]}, {"type": "DRUG", "name": "metoprolol", "armGroupLabels": ["Fixed-dose combination treatment-guided therapy", "PRA-guided therapy"]}, {"type": "DRUG", "name": "lisinopril/hydrochlorothiazide", "description": "This is a combination pill", "armGroupLabels": ["Fixed-dose combination treatment-guided therapy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic", "description": "At each study visit (approximately every 30 days), participants' BP will be checked. If BP is controlled (\\<140mmHG systolic and \\<90mmHG diastolic), then current medication will continue. If BP is uncontrolled, medication will be revised every 30 days (up to 120) until BP control is achieved.", "timeFrame": "4 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Systolic BP average during at least one recent (within 1 month) clinic or emergency room visit \u2265 150 mmHg, or diastolic BP average during at least one recent (within 1 month) clinic or emergency room visit \u2265 95 mmHg\n* Not currently taking BP-lowering medication\n* Clinician recommends pharmacologic treatment\n* Willing to make necessary study visits\n* Able to be contacted by phone\n* Has a primary care clinician\n* At least 18 years old\n\nExclusion Criteria:\n\n* Known secondary cause of hypertension\n* Pregnancy\n* Known diabetes, coronary artery disease or renal disease\n* Known sulfonamide allergy or history of gout\n* Participant's clinician recommends he/she not enroll\n* Hyponatremia, hypokalemia, hypernatremia, or hyperglycemia at baseline visit\n* Baseline visit systolic visit BP average \\< 140 mmHg and diastolic BP average \\< 90 mm Hg\n* Resting heart rate \\< 55 beats per minute", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Anthony Viera, MD, MPH", "affiliation": "Distinguished Associate Professor, Family Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "UNC Chapel Hill", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "PRA-guided Therapy", "description": "Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.\n\nHydrochlorothiazide\n\nLisinopril\n\nAmlodipine\n\nmetoprolol"}, {"id": "FG001", "title": "Fixed-dose Combination Treatment-guided Therapy", "description": "Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.\n\nAmlodipine\n\nmetoprolol\n\nlisinopril/hydrochlorothiazide"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "PRA-guided Therapy", "description": "Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.\n\nHydrochlorothiazide\n\nLisinopril\n\nAmlodipine\n\nmetoprolol"}, {"id": "BG001", "title": "Fixed-dose Combination Treatment-guided Therapy", "description": "Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.\n\nAmlodipine\n\nmetoprolol\n\nlisinopril/hydrochlorothiazide"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "17"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.6", "lowerLimit": "35", "upperLimit": "59"}, {"groupId": "BG001", "value": "46.7", "lowerLimit": "27", "upperLimit": "67"}, {"groupId": "BG002", "value": "47", "lowerLimit": "27", "upperLimit": "67"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "17"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic", "description": "At each study visit (approximately every 30 days), participants' BP will be checked. If BP is controlled (\\<140mmHG systolic and \\<90mmHG diastolic), then current medication will continue. If BP is uncontrolled, medication will be revised every 30 days (up to 120) until BP control is achieved.", "populationDescription": "6 participants withdrawn before study completion", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "4 months", "groups": [{"id": "OG000", "title": "PRA-guided Therapy", "description": "Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.\n\nHydrochlorothiazide\n\nLisinopril\n\nAmlodipine\n\nmetoprolol"}, {"id": "OG001", "title": "Fixed-dose Combination Treatment-guided Therapy", "description": "Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.\n\nAmlodipine\n\nmetoprolol\n\nlisinopril/hydrochlorothiazide"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "PRA-guided Therapy", "description": "Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.\n\nHydrochlorothiazide\n\nLisinopril\n\nAmlodipine\n\nmetoprolol", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 3, "otherNumAtRisk": 7}, {"id": "EG001", "title": "Fixed-dose Combination Treatment-guided Therapy", "description": "Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.\n\nAmlodipine\n\nmetoprolol\n\nlisinopril/hydrochlorothiazide", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 4, "otherNumAtRisk": 10}], "otherEvents": [{"term": "Electrolyte disturbance", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Lightheadedness", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 7}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 10}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Anthony Viera", "organization": "UNC Chapel Hil", "email": "viera@med.unc.edu", "phone": "919-966-0758"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008790", "term": "Metoprolol"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "D000017706", "term": "Lisinopril"}, {"id": "C000091365", "term": "Hydrochlorothiazide, lisinopril drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000002316", "term": "Cardiotonic Agents"}, {"id": "D000020011", "term": "Protective Agents"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M19924", "name": "Lisinopril", "asFound": "Amplitude", "relevance": "HIGH"}, {"id": "M11762", "name": "Metoprolol", "asFound": "Neonatal", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M229332", "name": "Hydrochlorothiazide, lisinopril drug combination", "asFound": "Antirheumatic Agents", "relevance": "HIGH"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M5572", "name": "Cardiotonic Agents", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}